Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec;39(12):1004-1007.
doi: 10.1016/j.tips.2018.09.008. Epub 2018 Nov 13.

Geroneuroprotectors: Effective Geroprotectors for the Brain

David Schubert  1 , Antonio Currais  1 , Joshua Goldberg  1 , Kim Finley  2 , Michael Petrascheck  3 , Pamela Maher  4
Affiliations
Review

Geroneuroprotectors: Effective Geroprotectors for the Brain

David Schubert et al. Trends Pharmacol Sci. 2018 Dec.

Abstract

Geroprotectors are compounds that slow the rate of biological aging and therefore may reduce the incidence of age-associated diseases such as Alzheimer's disease (AD). However, few have therapeutic efficacy in mammalian AD models. Here we describe the identification of geroneuroprotectors (GNPs), novel AD drug candidates that meet the criteria for geroprotectors.

Keywords: Alzheimer’s disease; aging; drug discovery; geroscience; multimorbidity; neuroprotection.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Geroneuroprotectors (GNPs) Share Molecular Pathways with Caloric Restriction and Geroprotectors.
Heatmap of molecular pathways activated (shown as red) or inhibited (shown as blue) by the different compounds is shown. White spaces denote that the effects were not determined whereas the hatched boxes depict publications showing both activation and inhibition. Data are compiled from [,,–20].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Moskalev A et al. (2015) Geroprotectors.org: a new, structured and curated database of current therpeutic interventions in aging and age-related disease. Aging (Albany N. Y.) 7, 616–628 - PMC - PubMed
    1. Johnson SC et al. (2013) mTOR is a key regulator of ageing and age-related disease. Nature 493, 338–345 - PMC - PubMed
    1. Salminen A and Kaarniranta K (2012) AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res. Rev 11, 230–241 - PubMed
    1. Petrascheck M et al. (2007) An antidepressant that extends lifespan in adult Caenorhabditis elegans. Nature 450, 553–556 - PubMed
    1. Prior M et al. (2014) Back to the future with phenotypic screening. ACS Chem. Neurosci 5, 503–513 - PMC - PubMed

Publication types

Substances